Vigil Neuroscience Inc (VIGL)

Currency in USD
8.050
0.000(0.00%)
Closed·
Showing Vigil Neuroscience historical data. For real-time data please try another search
Fair Value
Day's Range
8.0408.095
52 wk Range
1.3128.100
Key Statistics
Prev. Close
8.05
Open
8.05
Day's Range
8.04-8.095
52 wk Range
1.312-8.1
Volume
5.51M
Average Volume (3m)
1.65M
1-Year Change
129.34%
Book Value / Share
1.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIGL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Vigil Neuroscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Vigil Neuroscience Inc Company Profile

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company’s lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts. As of August 5, 2025, Vigil Neuroscience, Inc. operates as a subsidiary of Sanofi.

Compare VIGL to Peers and Sector

Metrics to compare
VIGL
Peers
Sector
Relationship
P/E Ratio
−4.4x0.0x−0.6x
PEG Ratio
−1.420.000.00
Price/Book
5.9x0.0x2.6x
Price / LTM Sales
-0.0x3.3x
Upside (Analyst Target)
−0.6%0.0%39.0%
Fair Value Upside
Unlock0.0%4.9%Unlock

Analyst Ratings

0 Buy
4 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.56 / -0.4314
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VIGL Income Statement

People Also Watch

35.900
SMR
+2.45%
4.740
ATAI
+3.72%
5.49
REPL
-3.17%
15.9000
COMM
+1.86%
1.850
SPRO
-1.07%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.